Combination of thiopurines and allopurinol: Adverse events and clinical benefit in IBD

Journal of Crohn's and Colitis

Volumn 4, Issue 4, 2010, Pages 444-449

  Govani, Shail M ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

6 Mercaptopurine; Allopurinol; Azathioprine; Inflammatory bowel disease; Shunting

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; DRUG METABOLITE; STEROID; TIOGUANINE;

ADULT; AGE; ANEMIA; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENTERITIS; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; HUMAN; INFECTION; INFECTION RISK; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MOUTH PAIN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIREMIA; VIRUS MENINGITIS;

6-MERCAPTOPURINE; ADULT; ALLOPURINOL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77957301876     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.02.009     Document Type: Article

References (22)

1. Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B., Pasternack B.S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980, 302:981-987.
2. Adler D.J., Korelitz B.I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990, 85:717-722.
3. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
4. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
5. George J., Present D.H., Pou R., Bodian C., Rubin P.H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996, 91:1711-1714.
6. Ewe K., Press A.G., Singe C.C., Stufler M., Ueberschaer B., Hommel G., et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993, 105:367-372.
7. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000545.
8. Prefontaine E., Sutherland L.R., Macdonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000067.
9. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
10. Sahasranaman S., Howard D., Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008, 64:753-767.
11. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651-662.
12. Ansari A., Hassan C., Duley J., Marinaki A., Shobowale-Bakre E.M., Seed P., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743-1750.
13. Cuffari C., Dassopoulos T., Turnbough L., Thompson R.E., Bayless T.M. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004, 2:410-417.
14. Zazgornik J., Kopsa H., Schmidt P., Pils P., Kuschan K., Deutsch E. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. Int J Clin Pharmacol Ther Toxicol 1981, 19:96-97.
15. Berns A., Rubenfeld S., Rymzo W.T., Calabro J.J. Hazard of combining allopurinol and thiopurine. N Engl J Med 1972, 286:730-731.
16. Chocair P., Duley J., Simmonds H.A., Cameron J.S., Ianhez L., Arap S., et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993, 342:83-84.
17. Sparrow M.P., Hande S.A., Friedman S., Lim W.C., Reddy S.I., Cao D., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441-446.
18. Sparrow M.P., Hande S.A., Friedman S., Cao D., Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209-214.
19. Ansari A., Elliott T., Baburajan B., Mayhead P., O'Donohue J., Chocair P., et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:734-741.
20. Witte T.N., Ginsberg A.L. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008, 22:181-185.
21. Hanauer D. EMERSE: The Electronic Medical Record Search Engine. AMIA Annu Symp Proc 2006, 941.
22. de Boer N.K., van Bodegraven A.A., Jharap B., de Graaf P., Mulder C.J. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:686-694.